Accéder au contenu
MilliporeSigma

Y0000119

Hydroxyurée

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Hydroxycarbamide

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

Changer de vue

A propos de cet article

Formule linéaire :
NH2CONHOH
Numéro CAS:
Poids moléculaire :
76.05
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
1741548
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider


grade

pharmaceutical primary standard

API family

hydroxycarbamide

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

NC(=O)NO

InChI

1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)

InChI key

VSNHCAURESNICA-UHFFFAOYSA-N

Gene Information

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Hydroxycarbamide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Anti-néoplasique. Inactive la ribonucléoside réductase par formation d′un radical libre nitroxyde qui se lie à un radical libre tyrosyle sur le site actif de l′enzyme. Ceci bloque la synthèse des désoxynucléotides, ce qui inhibe la synthèse d′ADN et induit la synchronisation ou la mort cellulaire en phase S.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.


Still not finding the right product?

Explore all of our products under Hydroxyurée


pictograms

Health hazard

signalword

Danger

hcodes

Hazard Classifications

Muta. 1B - Repr. 2

Classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents



A Tefferi et al.
Leukemia, 28(12), 2300-2303 (2014-05-06)
The impact of calreticulin (CALR) mutations on long-term survival in essential thrombocythemia (ET) was examined in 299 patients whose diagnosis predated 2006. Mutational frequencies were 53% for Janus kinase 2 (JAK2), 32% for CALR and 3% for MPL; the remaining
Patrick T McGann et al.
Current opinion in hematology, 18(3), 158-165 (2011-03-05)
Sickle cell anemia (SCA) is a well characterized severe hematological disorder with substantial morbidity and early mortality. Hydroxyurea is a potent inducer of fetal hemoglobin, and evidence over the past 25 years has documented its laboratory and clinical efficacy for
Alessandro M Vannucchi et al.
The New England journal of medicine, 372(5), 426-435 (2015-01-30)
Ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, was shown to have a clinical benefit in patients with polycythemia vera in a phase 2 study. We conducted a phase 3 open-label study to evaluate the efficacy and safety of



Numéro d'article de commerce international

RéférenceGTIN
Y000011904061837567834